The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...

The report also showed that the PBMs earned $1.4 billion from spread pricing, or when PBMs bill plan sponsors more than they reimburse pharmacies. An FTC spokesperson did not comment on any ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Here is a hard truth for those of us who are care providers: Americans are unsatisfied with the country's healthcare system.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

The biggest pharmacy benefit managers have made efforts to improve relationships with pharmacies, health insurers, employers ...

It’s not only insulin. The FTC on Jan. 14 released a report charging PBMs with driving up prices for specialty drugs to treat ...